Aptose Biosciences Inc (APTO)

[Norm2]

More on LOR 2040
Phase I LOR 2040 results
"Lorus Therapeutics announces publication of a clinical study demonstrating "encouraging results" with LOR-2040 in combination with Cytarabine in patients with acute Myeloid Leukemia (LRP) 0.10 : Co announces publication by an Ohio State University clinical team of a paper entitled "Phase I Study of GTI-2040". This was the first clinical study in AML with GTI-2040, now known as LOR-2040. All patients in the study received LOR-2040 and high dose cytarabine in therapeutic doses within a dose escalating design, which determined a well-tolerated recommended Phase II dose. The authors have also now reported for the first time that outcomes of complete response were associated with high pre-treatment levels of R2, which were statistically significant compared to nonresponders. This finding suggests that pre-treatment R2 levels may be a predictor of response, and provide a possible basis for treatment stratification to LOR-2040 and high dose cytarabine combination. Favorable disease responses included complete responses in 35% of the 23 patients and significant cytoreduction of leukemic blasts in two others. The authors concluded that LOR-2040 in combination with high dose cytarabine is feasible, is active against its target R2, and "holds promise in younger patients with refractory or relapsed AML"

A ways from making money, but progress.

Norman